Scale up drug screens with sensitive high-throughput transcriptomics

Exclusive early access to RNA-seq technology for large-scale drug discovery

Expanding your drug discovery efforts?

Large-scale drug screens are necessary to prioritize promising compounds based on cellular transcriptomic response, but conventional RNA-seq workflows can’t keep up—researchers are struggling with limited throughput, complicated workflows, high costs, and unreliable data dropouts. High-throughput transcriptomic screens need scalable, sensitive, and cost-effective technology to help you sift through thousands of samples and put you on the fastest path to market with your next successful drug.

Screen compounds faster with an optimized, low-cost kit

We designed our new transcriptomic solution to deliver highly sensitive RNA-seq data with rapid turnaround and minimal costs. The kit features sample pooling, barcoding, and workflow automation to help you scale up drug screens while reducing manual effort and reagent costs. With efficient 3′-end counting and error-correcting unique molecular identifiers (UMIs), this technology ensures confident target identification on the first try, minimizing data loss and avoiding costly experimental repeats. 

Join the early access program

Register below to receive exclusive pre-launch access to our new SMART-Seq mRNA 3′ DE HT (with UMIs)! To be considered, please use the "Comments" section of the form below to briefly describe how SMART-Seq mRNA 3′ DE HT (with UMIs) would support your project. A limited number of kits are available for early access. Submissions close on 8.31.26.

Webinar: Scale up drug screens with cost-effective high-throughput technology